Literature DB >> 9756944

Differential signaling by the epidermal growth factor-like growth factors neuregulin-1 and neuregulin-2.

C S Crovello1, C Lai, L C Cantley, K L Carraway.   

Abstract

The neuregulins comprise a subfamily of epidermal growth factor (EGF)-like growth factors that elicit diverse cellular responses by activating members of the ErbB family of receptor tyrosine kinases. Although neuregulin-1 and neuregulin-2 are both binding ligands for the ErbB3 and ErbB4 receptors, they exhibit distinct biological activities depending on cellular context. In MDA-MB-468 human mammary tumor cells, neuregulin-2beta (NRG2beta) inhibits cell growth, whereas neuregulin-1beta (NRG1beta) does not. In these cells, NRG2beta appears to preferentially act through the EGF receptor, stimulating receptor tyrosine phosphorylation and the recruitment of phospholipase C-gamma, Cbl, SHP2, and Shc to that receptor. NRG1beta preferentially acts through ErbB3 in these cells by stimulating the tyrosine phosphorylation and recruitment of phosphatidylinositol 3-kinase and Shc to that receptor. In MDA-MB-453 cells, both NRG1beta and NRG2beta stimulate the tyrosine phosphorylation of the ErbB2 and ErbB3 receptors to similar extents, but only NRG1beta potently stimulates morphological changes consistent with their differentiation. The profiles of SH2 domain-containing proteins that are efficiently recruited to activated receptors differ for the two factors. These observations indicate that despite their overlapping receptor specificity, the neuregulins exhibit distinct biological and biochemical properties. Since both of these cell lines express only two of the known ErbB receptors, our results imply that EGF-like ligands might elicit differential signaling within the context of a single receptor heterodimer.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9756944     DOI: 10.1074/jbc.273.41.26954

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  24 in total

1.  Akt-mediated survival of oligodendrocytes induced by neuregulins.

Authors:  A I Flores; B S Mallon; T Matsui; W Ogawa; A Rosenzweig; T Okamoto; W B Macklin
Journal:  J Neurosci       Date:  2000-10-15       Impact factor: 6.167

Review 2.  Neuregulin signaling via erbB receptor assemblies in the nervous system.

Authors:  Sean Murphy; Randy Krainock; Muly Tham
Journal:  Mol Neurobiol       Date:  2002-02       Impact factor: 5.590

Review 3.  Multiple personalities of neuregulin gene family members.

Authors:  D A Talmage; L W Role
Journal:  J Comp Neurol       Date:  2004-04-26       Impact factor: 3.215

Review 4.  Signalling between microvascular endothelium and cardiomyocytes through neuregulin.

Authors:  Emily M Parodi; Bernhard Kuhn
Journal:  Cardiovasc Res       Date:  2014-01-29       Impact factor: 10.787

5.  Axonal neuregulin 1 type III activates NF-kappaB in Schwann cells during myelin formation.

Authors:  Allison S Limpert; Bruce D Carter
Journal:  J Biol Chem       Date:  2010-04-01       Impact factor: 5.157

6.  ErbB receptors in fetal endothelium--a potential linkage point for inflammation-associated neonatal disorders.

Authors:  Wolfgang Bueter; Olaf Dammann; Katja Zscheppang; Elena Korenbaum; Christiane E L Dammann
Journal:  Cytokine       Date:  2007-03-26       Impact factor: 3.861

Review 7.  Tumour-associated mesenchymal stem/stromal cells: emerging therapeutic targets.

Authors:  Yufang Shi; Liming Du; Liangyu Lin; Ying Wang
Journal:  Nat Rev Drug Discov       Date:  2016-11-04       Impact factor: 84.694

8.  Differential utilization and localization of ErbB receptor tyrosine kinases in skin compared to normal and malignant keratinocytes.

Authors:  S W Stoll; S Kansra; S Peshick; D W Fry; W R Leopold; J F Wiesen; M Sibilia; T Zhang; Z Werb; R Derynck; E F Wagner; J T Elder
Journal:  Neoplasia       Date:  2001 Jul-Aug       Impact factor: 5.715

9.  Stabilization of the E3 ubiquitin ligase Nrdp1 by the deubiquitinating enzyme USP8.

Authors:  Xiuli Wu; Lily Yen; Lisa Irwin; Colleen Sweeney; Kermit L Carraway
Journal:  Mol Cell Biol       Date:  2004-09       Impact factor: 4.272

Review 10.  The ERBB3 receptor in cancer and cancer gene therapy.

Authors:  G Sithanandam; L M Anderson
Journal:  Cancer Gene Ther       Date:  2008-04-11       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.